Results 171 to 180 of about 20,698 (251)

Comment on Klein et al. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. [PDF]

Diabetes Care
Tang B, Ma D, Liu J.
europepmc   +1 more source

GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims No studies have investigated the synergistic effectiveness of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after ...
J. M. Samuels, C. R. Williams, M. B. Patel, W. H. Self, L. M. Funk, C. Roumie, M. D. Spann, C. J. Northup, F. Ye, R. Irlmeier, I. Sohn, Y. Zhu, K. Niswender   +12 more
wiley   +1 more source

Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review. [PDF]

Endocrinol Diabetes Metab
Bawadi H, Abuhijleh H, Nofal M, Zakaria ZZ, Al-Asmakh M.   +4 more
europepmc   +1 more source

Predicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN‐1 Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To assess change in long‐term predicted 10‐year cardiometabolic risk (Type 2 diabetes [T2D] and cardiovascular disease [CVD]) in adults with overweight or obesity without T2D. Methods This post hoc analysis used data from ATTAIN‐1, a Phase 3 trial in adults (≥ 18 years) with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 with
Shraddha Shinde, Florian Kahles, Simona Vasileva‐Metodiev, Ryan Griffin, Hong Liu‐Seifert, Jeremie Lebrec, Neena A. Xavier, Runjia Li, Suzanne R. Klise, Ambrish Singh, Jens Aberle   +10 more
wiley   +1 more source

Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications. [PDF]

Cureus
Mohan V, Kalra S, Ahluwalia A, Gangopadhyay KK, Bhattacharyya A, Saboo B, Kesavadev J, Ramakrishnan S, Lakhani OJ, Nagendra L, Sahoo AK, Joshi A, V Sri N, Joshi SR.   +13 more
europepmc   +1 more source

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the effect of semaglutide on body composition and physical function. Materials and Methods The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m2 to once‐weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks.
Jøran Hjelmesæth, Suhas Bhat, W. Timothy Garvey, Kristoffer Jensen Kolnes, Jennifer Linge, Ildiko Lingvay, Niklas Kahr Rasmussen, Julio Rosenstock, Sean Wharton   +8 more
wiley   +1 more source

Salcaprozate Sodium as a Permeation Enhancer-Mechanism, Applications and Unresolved Questions. [PDF]

Pharmaceutics
Dinkov B, Koleva N, Stavreva G.
europepmc   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Response to Comment on Klein et al. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. [PDF]

Diabetes Care
Menacher A, Mayrdorfer M, Lingvay I, Klein KR.   +3 more
europepmc   +1 more source

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre, Giulia Di Dalmazi, Federica Carrieri, Giorgia Centorame, Luigi Piacentino, Sara Coluzzi, Gloria Formoso   +6 more
wiley   +1 more source